Royal Bank of Canada Buys 7,818 Shares of Mesa Laboratories, Inc. $MLAB

Royal Bank of Canada boosted its stake in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) by 143.3% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 13,275 shares of the medical instruments supplier’s stock after acquiring an additional 7,818 shares during the period. Royal Bank of Canada’s holdings in Mesa Laboratories were worth $1,173,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. lifted its stake in Mesa Laboratories by 5,366.7% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 322 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Mesa Laboratories during the fourth quarter valued at about $27,000. Kestra Advisory Services LLC bought a new stake in shares of Mesa Laboratories in the fourth quarter worth about $55,000. BNP Paribas Financial Markets increased its holdings in shares of Mesa Laboratories by 115.3% in the second quarter. BNP Paribas Financial Markets now owns 786 shares of the medical instruments supplier’s stock worth $74,000 after purchasing an additional 421 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Mesa Laboratories by 432.9% in the second quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier’s stock worth $79,000 after purchasing an additional 684 shares during the last quarter. 90.60% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

MLAB has been the subject of a number of research reports. Wall Street Zen lowered Mesa Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 15th. Weiss Ratings raised Mesa Laboratories from a “sell (d)” rating to a “hold (c-)” rating in a research note on Tuesday, August 11th. Finally, Wells Fargo & Company lifted their price objective on Mesa Laboratories from $94.00 to $110.00 and gave the stock an “equal weight” rating in a research note on Friday, August 14th. Three research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $110.00.

Insider Activity at Mesa Laboratories

In related news, CEO Siddhartha Kadia acquired 7,093 shares of Mesa Laboratories stock in a transaction on Thursday, August 13th. The shares were bought at an average cost of $112.80 per share, with a total value of $800,090.40. Following the completion of the purchase, the chief executive officer directly owned 7,093 shares of the company’s stock, valued at $800,090.40. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CAO Lyndsey Elizabeth Crennen sold 442 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total value of $39,559.00. Following the sale, the chief accounting officer owned 2,020 shares in the company, valued at approximately $180,790. This trade represents a 17.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 15,370 shares of company stock valued at $1,570,213 over the last ninety days. 2.80% of the stock is currently owned by company insiders.

Mesa Laboratories Price Performance

MLAB stock opened at $119.15 on Friday. Mesa Laboratories, Inc. has a 52 week low of $58.83 and a 52 week high of $121.90. The firm has a market capitalization of $667.24 million, a P/E ratio of 141.85 and a beta of 0.92. The company has a fifty day simple moving average of $101.08 and a two-hundred day simple moving average of $97.04. The company has a quick ratio of 1.32, a current ratio of 1.79 and a debt-to-equity ratio of 0.73.

Mesa Laboratories (NASDAQ:MLAB) last posted its earnings results on Monday, August 10th. The medical instruments supplier reported $2.68 earnings per share for the quarter. The firm had revenue of $60.14 million for the quarter. Mesa Laboratories had a net margin of 1.92% and a return on equity of 22.72%.

Mesa Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Monday, August 31st will be given a $0.16 dividend. The ex-dividend date is Monday, August 31st. This represents a $0.64 annualized dividend and a yield of 0.5%. Mesa Laboratories’s dividend payout ratio (DPR) is currently 76.19%.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.